{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Kungwankiattichai S"],"pubmed_abstract":["<h4>Introduction</h4>Hypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients.<h4>Materials and methods</h4>The Embase, MEDLINE, and Cochrane Central Register of Controlled Trials databases were independently searched by two investigators to identify relevant studies published inception to 18 November 2021. These trials compared HMA maintenance to observation following allo-SCT for AML or myelodysplastic syndrome.<h4>Results</h4>The meta-analysis eligibility criteria were fulfilled by 14 studies. The overall survival and relapse-free survival of the HMA maintenance group were superior to the observation group, with a pooled risk ratio (RR) of 1.38 and"],"journal":["Frontiers in medicine"],"pagination":["801632"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8887643"],"repository":["biostudies-literature"],"pubmed_title":["Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis."],"pmcid":["PMC8887643"],"pubmed_authors":["Kuchenbauer F","Roy C","Ponvilawan B","Owattanapanich W","Kungwankiattichai S","Tunsing P"],"additional_accession":[]},"is_claimable":false,"name":"Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.","description":"<h4>Introduction</h4>Hypomethylating agents (HMAs) seem to have a range of properties favorable to post-allogeneic hematopoietic stem cell transplantation (allo-SCT) maintenance in acute myeloid leukemia (AML) patients.<h4>Materials and methods</h4>The Embase, MEDLINE, and Cochrane Central Register of Controlled Trials databases were independently searched by two investigators to identify relevant studies published inception to 18 November 2021. These trials compared HMA maintenance to observation following allo-SCT for AML or myelodysplastic syndrome.<h4>Results</h4>The meta-analysis eligibility criteria were fulfilled by 14 studies. The overall survival and relapse-free survival of the HMA maintenance group were superior to the observation group, with a pooled risk ratio (RR) of 1.38 and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-04T17:07:00.4Z","creation":"2025-04-21T16:46:23.259Z"},"accession":"S-EPMC8887643","cross_references":{"pubmed":["35242779"],"doi":["10.3389/fmed.2022.801632"]}}